Literature DB >> 18164508

Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids.

Alexandre Louvet1, Emmanuel Diaz, Sébastien Dharancy, Hugues Coevoet, Frédéric Texier, Thierry Thévenot, Pierre Deltenre, Valérie Canva, Christophe Plane, Philippe Mathurin.   

Abstract

BACKGROUND/AIMS: In severe alcoholic hepatitis (AH), 40% of patients will obtain no benefit from corticosteroids. Improvement in management of non-responders is warranted and only pentoxifylline can be considered an alternative. A two-step strategy was evaluated consisting of early withdrawal of corticosteroids and a switch to pentoxifylline for 28 additional days in non-responders identified using early change in bilirubin level.
METHODS: One hundred and twenty-one patients with AH were treated prospectively with corticosteroids, and the two-step strategy was proposed to 29 non-responders treated according to a two-step strategy who were compared to 58 matched non-responders treated with corticosteroids only.
RESULTS: Clinical and biological features of the two groups were similar. There was no survival improvement at 2 months in patients treated with the two-step strategy compared to controls: 35.5+/-6.3% vs 31+/-8.6%. After 21 days, biological evolution was similar for prothrombin time (-0.25s vs +0.2s), bilirubin (0.8 mg/dl vs 2.03 mg/dl) and creatinine (+0.16 mg/dl vs -0.7 mg/dl). In multivariate analysis, only age, evolution of bilirubin during the first week, creatinine and DF were associated with 2-month survival.
CONCLUSIONS: Non-responders to corticosteroids do not obtain any benefit from an early switch to pentoxifylline. Thus, the issue of management of non-responders remains unresolved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18164508     DOI: 10.1016/j.jhep.2007.10.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  47 in total

1.  Corticosteroids and pentoxifylline for the treatment of alcoholic hepatitis: Current status.

Authors:  Ashwani K Singal; Ishmeet Walia; Anjna Singal; Roger D Soloway
Journal:  World J Hepatol       Date:  2011-08-27

2.  Recent advances in alcoholic hepatitis.

Authors:  Jennifer Veryan; E H Forrest
Journal:  Frontline Gastroenterol       Date:  2019-05-21

3.  Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial).

Authors:  Sandeep Singh Sidhu; Omesh Goyal; Preeti Singla; Dinesh Gupta; Ajit Sood; Rajoo Singh Chhina; Ravinder Kumar Soni
Journal:  Dig Dis Sci       Date:  2012-03-03       Impact factor: 3.199

Review 4.  Alcoholic liver disease: mechanisms of injury and targeted treatment.

Authors:  Alexandre Louvet; Philippe Mathurin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

Review 5.  Severe alcoholic hepatitis-current concepts, diagnosis and treatment options.

Authors:  Won Kim; Dong Joon Kim
Journal:  World J Hepatol       Date:  2014-10-27

Review 6.  The knowns and unknowns of treatment for alcoholic hepatitis.

Authors:  Tejasav S Sehrawat; Mengfei Liu; Vijay H Shah
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-05

7.  Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.

Authors:  Srinivasan Dasarathy; Mack C Mitchell; Bruce Barton; Craig J McClain; Gyongyi Szabo; Laura E Nagy; Svetlana Radaeva; Arthur J McCullough
Journal:  Contemp Clin Trials       Date:  2020-07-31       Impact factor: 2.226

Review 8.  Grand Rounds: Alcoholic Hepatitis.

Authors:  Ashwani K Singal; Alexandre Louvet; Vijay H Shah; Patrick S Kamath
Journal:  J Hepatol       Date:  2018-06-13       Impact factor: 25.083

9.  Pilot study of pentoxifylline in hepatopulmonary syndrome.

Authors:  Rajasekhar Tanikella; George M Philips; Dorothy K Faulk; Steven M Kawut; Michael B Fallon
Journal:  Liver Transpl       Date:  2008-08       Impact factor: 5.799

10.  Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome?

Authors:  Stelios-F Assimakopoulos; Konstantinos-C Thomopoulos; Chrisoula Labropoulou-Karatza
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.